1 study found for:    NCT01592136
Show Display Options
Rank Status Study
1 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib

Indicates status has not been verified in more than two years